P

Phoenix Children's Hospital | Main - Orthopedics & Sport Injury

Research site

(Unclaimed)

Location

1919 East Thomas Rd, Phoenix, Arizona, United States of America

Site insights

Top conditions

Top treatments

DFMO

Vinblastine

Prednisone

sorafenib

vorinostat

Carbetocin

Dexamethasone

Nitric Oxide

INO

Guselkumab

Parent organization

This site is a part of Phoenix Children's Hospital

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 19 total trials

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (MACARONI-23)

The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at th...

Enrolling

Crohn's Disease

Drug: Guselkumab

Drug: Placebo

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling

Chronic Kidney Disease

Proteinuria

Drug: Finerenone (Kerendia, BAY94-8862)

Drug: Placebo

Locations recently updated

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery)....

Invitation-only

Fragile X Syndrome

Drug: ZYN002 - Cannabidiol Transdermal Gel

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with st...

Enrolling

Neuroblastoma

Drug: DFMO

Drug: vorinostat